The findings of our study build upon and confirm the broader findings of Tandon et al. regarding the effects of angiotensin-converting enzyme (ACE) inhibitors and ARBs on portal hypertension in liver cirrhosis [38]. This evidence concerns the gene ACE and portal hypertension.